Cutia Therapeutics (HKG:2487)

Hong Kong · Delayed Price · Currency is HKD

0.8600

+0.0100 (1.18%)

Oct 9, 2026, 3:26 PM HKT

Market Cap	319.06M -89.8%
Revenue (ttm)	383.95M +32.9%
Net Income	-324.64M
EPS	-0.92
Shares Out	373.17M
PE Ratio	n/a
Forward PE	24.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,000
Open	0.8500
Previous Close	0.8500
Day's Range	0.8050 - 0.8950
52-Week Range	0.7400 - 9.1900
Beta	0.78
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 1, 2026

About Cutia Therapeutics

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management medication. The company provides CU-40102, a topical finasteride spray for androgenetic alopecia treatment; and CU-10201, a to... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2019

Employees 268

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2487

Full Company Profile

Financial Performance

In 2025, Cutia Therapeutics's revenue was 336.15 million, an increase of 20.22% compared to the previous year's 279.62 million. Losses were -340.19 million, -21.58% less than in 2024.

Financial numbers in CNY Financial Statements